LLY vs OGN · P/E 39, rev $22.97B vs P/E 3.4, rev $3.02B
Eli Lilly and Company (LLY) versus Organon & Co (OGN) — a side-by-side from cached financials, not a winner call.
Eli Lilly and Company (LLY) is a drug manufacturers - general company listed on NYSE. It is led by David Ricks.
Organon & Co (OGN) is a drug manufacturers - general company listed on US.
Latest reported LLY revenue for 2026-06-30 was $22.97B. Net income was $7.09B. Revenue was up 16.0% from 2026-03-31 to 2026-06-30. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
Latest reported OGN revenue for 2026-06-30 was $3.02B. Net income was $254.0M. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
LLY currently screens at market cap $991.62B and trailing P/E 39.5. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
Not investment advice. Open the LLY and OGN stock pages for the full models.
Not investment advice.